▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening

Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM. This large-scale or...

Business Wire

SAN DIEGO: Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM. This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.

Screening of a large panel of patient-derived organoids is enabled using Crown Bioscience’s unique assay-ready (AR) organoid technology. Recent posters presented at the AACR annual meeting and ANE international conference 2023 demonstrate the performance of assay-ready organoids against freshly prepared organoids – the traditional methodology. The study demonstrated the utility of OrganoidXplore and revealed:

  • Highly Robust Performance: Both the assay-ready and original methods consistently performed with high accuracy across multiple assays.
  • Accelerated Timelines and Reduced Costs: OrganoidXplore slashed project timelines by two-thirds, when compared to standard methods.
  • Reliable and Reproducible Drug Response Comparisons: Both methods showed analogous results in cell viability (CTG) and high content imaging (HCI) assays when tested with standard drugs such as paclitaxel, carboplatin, and cisplatin.

OrganoidXplore transcends traditional 2D cell culture systems in terms of patient relevance, heralding a significant leap in preclinical drug screening. By accurately replicating the genomic, morphological, and pathophysiological attributes of original tumors, researchers are now equipped to screen against an extensive range of predictive models. Results can be obtained within an expedited timeframe of just six weeks, magnifying research speed three-fold and anchoring its promise on the robustness and reproducibility of its advanced assay-ready technology.

Researchers can choose between a comprehensive Full Panel or a specialized KRAS Panel to meet their specific goals. The Full Panel currently comprises 50 organoid models covering seven cancer indications, which are also available as companion Patient-Derived Xenografts (PDX). The KRAS Panel specifically targets four cancer indications, with 25 models covering a broad range of KRAS mutations. These models are also available as PDX, allowing for a seamless transition to follow-on studies.

In combination with comprehensive next-generation sequencing (NGS) characterization, including whole exome sequencing (WES) and RNA sequencing (RNAseq), OrganoidXplore enables expedited biomarker identification, highly relevant mechanism of action studies, selection of indications and/or models, investigation of drug repurposing, and improved patient stratification.

Leo Price, PhD, Senior Vice President, In Vitro and Head of Crown Bioscience Netherlands, said: “OrganoidXplore addresses the exacting demands of pioneering research initiatives by offering a diverse selection of models that cover a wide spectrum of genetic backgrounds and mutations. Thanks to the implementation of innovative organoid cryopreservation technology automation and assay automation, OrganoidXplore’s precision, speed, and reproducibility are unrivaled.”

Crown Bioscience remains steadfast in its commitment to driving innovations in oncology research, evidenced by the introduction of OrganoidXplore, designed with the mission to accelerate drug discovery.

###

About Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology and immuno-oncology. We are the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology, offering over 600 organoid models spanning 22 cancer indications. In addition, we have developed the largest commercially available PDX collection in the world. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 13 facilities across the United States, Europe, and Asia.

For more information or to get in touch, please visit www.crownbio.com

Contacts

Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

BostonGene to Showcase its Multimodal AI Platform Advancing Drug Development…

BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that six abstracts have been accepted at the 2025 ASCO…

Udemy Launches AI-Powered Role Play to Coach Professionals on Business…

Udemy (Nasdaq: UDMY), a leading AI-powered reskilling platform, today announced the launch of Role Play, a new AI-powered offering that helps learners…

LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure…

#AI--LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed…

DEWA Receives Applications From Local and International Companies Seeking…

Dubai Electricity and Water Authority (DEWA) has started to receive applications for participation in the 27th edition of the Water, Energy, Technology,…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!